^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ARV-766

    i
    Other names: ARV-766
    Associations

    News

    Trials
    Company:
    Arvinas
    Drug class:
    Androgen receptor degrader
    Related drugs:
    Associations

    News

    Trials
    6ms
    A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1/2, N=220, Recruiting, Arvinas Androgen Receptor, Inc. | N=150 --> 220 | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    abiraterone acetate • ARV-766
    1year
    Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer (AACR 2023)
    ARV-766 significantly and dose-dependently inhibits tumor growth in murine LNCaP and VCaP xenograft models, including an enzalutamide-insensitive non-castrated VCaP model. These preclinical data supported the clinical development of ARV-766 for the treatment of men with metastatic CRPC. Selected pre-clinical data along with the chemical structure of ARV-766 will be presented.
    Metastases
    |
    AR (Androgen receptor)
    |
    AR mutation • AR L702H
    |
    Xtandi (enzalutamide capsule) • ARV-766
    over1year
    A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC). (ASCO-GU 2023)
    Patients enrolled in the cohort expansion must have received 1–3 prior NHAs (eg, abiraterone or enzalutamide) and ≤2 prior chemotherapy regimens. Enrollment in the phase 2 expansion study is ongoing. Clinical trial information: NCT05067140.
    P2 data • Metastases
    |
    AR (Androgen receptor)
    |
    AR mutation • AR T878A • AR H875Y • AR L702H • AR wild-type
    |
    Xtandi (enzalutamide capsule) • abiraterone acetate • ARV-766